Skip to main content

Table 5 Disease-free survival or recurrence-free survival among patients with colorectal cancer according to CIMP status

From: Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

CIMP definition

First author (year)

Subgroup

Subgroup size

Analysis

Survival

HR (95 % CI)

Comparison group

p value

Covariates adjusted for

CIMP+/ CIMP-H

CIMP-L

CRC patients

         

 D 2

Kalady (2009) [17]

All

357

M

RFS

2.08 (0.65–6.65)a

 

CIMP−

0.21

Age, sex, stage, MSIb

 D 9

Hokazono (2014) [33]

All

104

M

RFS

0.29 (0.02–1.42)

 

CIMP−

0.15

Not report

CRC patients by cancer stages

         

 D 9

Hokazono (2014) [33]

I–II

50

M

RFS

0.01 (0.00–2.28)

 

CIMP−

 

Not report

 D 1

Ju (2011) [38]

I–III

53

M

RFS

1.05 (0.33–3.39)

 

CIMP−

0.93

Age, sex, stage

 D 2

Min (2011) [25]

I–III

124

M

RFS

0.81 (0.21–3.14)

 

CIMP−

 

Age, sex, stage, BRAF, KRAS, MGMTb

 D 6

Ward (2003) [37]

I–III

476

U

RFS

0.90 (0.50–2.00)

 

CIMP−

0.94

No

 D 8

Jover (2011) [5]

II–III

196

M

DFS

1.20 (0.80–2.00)

 

CIMP−

0.40

Age, stage, adjuvant chemotherapy

 D 10

Wang (2014) [36]

II–III

50

M

DFS

2.94 (1.19–7.22)

 

CIMP−

0.02

Stage, location

 D 2

Donada (2013) [40]

II, colon

120

M

DFS

0.58

 

CIMP−

0.20

All variablesc

 D 9

Hokazono (2014) [33]

III

39

M

RFS

0.45 (0.01–2.23)

 

CIMP−

 

Not report

CRC patients by location of CRC

         

 D 3

Bae (2013) [28]

Proximal

165

M

DFS

1.00 (0.53–1.88)

 

CIMP−

0.99

Stagec

 D 3

Bae (2013) [28]

Distal

327

M

DFS

1.31 (0.51–3.36)

 

CIMP−

0.58

Stagec

 D 2

Donada (2013) [40]

Colon, II

120

M

DFS

0.58

 

CIMP−

0.20

All variablesc

 D 1

Samowitz (2009) [20]

Rectal

990

M

DFS

1.32 (0.88–1.97)

 

CIMP−

 

Age, stage, BRAF, MSI, KRAS, TP53d

 D 3

Bae (2013) [28]

Rectal

242

M

DFS

2.90 (1.04–8.08)

 

CIMP−

0.04

Stagec

CRC patients by microsatellite instability

        

 D 3

Kim (2013) [29]

MSI

220

M

DFS

2.25 (1.11–4.57)

 

CIMP−

0.03

Age, stage, differentiation, BRAFe

  1. CI confidence interval, DFS disease-free survival, HR hazard ratio, M multivariate analysis, RFS recurrence-free survival, U univariate analysis
  2. aThe original data of HR (95 % CI) was 0.48 (0.15–1.53) derived from CIMP− compared with CIMP+
  3. bOther covariates included in the multivariate analysis are: differentiation, chemotherapy
  4. cOriginal paper mentioned the multivariate analysis including all clinical, pathological and molecular variables
  5. dMultivariate analysis adjusted BRAF, MSI, KRAS, and TP53, in addition to age and stage, the result adjusted for only age and stage was 1.45 (1.02–2.07)
  6. eOther covariates included in the multivariate analysis are Crohn’s-like lymphoid reaction and peritumoral lymphocytic reaction
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us